Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06890455

Enrollment

120

Registered

2025-03-24

Start date

2025-03-31

Completion date

2026-02-28

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Calprotectin in Intestinal Protozoa

Brief summary

Calprotectin extracted from stool can be detected easily using ELISA. Numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation This study aims to detect the relationship between fecal calprotectin and Blastocystis hominis and Entamoeba histolytica infections.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

120 fecal samples will be collected as the following: * 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica. * 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection. * 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).

Exclusion criteria

* persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis

Design outcomes

Primary

Measure	Time frame
Prevalence of Blastocystis and Entamoeba	2 months

Secondary

Measure	Time frame
Number of persons have high fecal calprotectin	6 months

Countries

Egypt

Contacts

Primary ContactYoustina Kamel Boles, Demonstrator

youstena.kamel@med.sohag.edu.eg+20 12 73435308

Outcome results